A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1
Phase of Trial: Phase III
Latest Information Update: 25 May 2017
At a glance
- Drugs Brodalumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms AMVISION-1
- Sponsors Amgen
- 09 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015, according to ClinicalTrials.gov record.
- 09 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015, according to ClinicalTrials.gov record.
- 28 Jul 2015 Planned End Date changed from 1 Apr 2018 to 1 Sep 2015 as reported by ClinicalTrials.gov.